Works Cited

1. National Center for Health Statistics. Prevalence of Overweight, Obesity, and Extreme Obesity Among Adults: United States, Trends 1960–1962 Through 2013–Available at https://www.cdc.gov/nchs/data/hestat/obesity_adult_13_14/obesity_adult_13_14.pdf. Last accessed December 20, 2017.

2. Centers for Disease Control and Prevention. Data Trends and Maps: Physical Activity—Behavior. Available at https://nccd.cdc.gov/dnpao_dtm/rdPage.aspx?rdReport=DNPAO_DTM.ExploreByTopic&islClass=PA&islTopic=PA1&go=GO. Last accessed December 20, 2017.

3. Centers for Disease Control and Prevention. Press Release: Only 1 in 10 Adults Get Enough Fruits or Vegetables. Available at https://www.cdc.gov/media/releases/2017/p1116-fruit-vegetable-consumption.html. Last accessed December 20, 2017.

4. Centers for Disease Control and Prevention. State Indicator Report on Fruits and Vegetables, 2009. Available at https://www.cdc.gov/nutrition/downloads/StateIndicatorReport2009.pdf. Last accessed December 20, 2017.

5. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff (Millwood). 2009;28(5):w822-w831.

6. U.S. Department of Health and Human Services, Public Health Service, Office of the Surgeon General. The Surgeon General's Call to Action to Prevent and Decrease Overweight and Obesity. Available at https://www.ncbi.nlm.nih.gov/books/NBK44206. Last accessed December 20, 2017.

7. Allison DB, Fontaine KR, Manson JE, Stevens J, VanItallie TB. Annual deaths attributable to obesity in the United States.JAMA. 1999;282(16):1530-1538.

8. Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deaths associated with underweight, overweight, and obesity. JAMA. 2005;293(15):1861-1867.

9. Bray B. Definitions and proposed current classification of obesity. In: Bray B, Bouchard C (eds). Handbook of Obesity. 4th ed. New York, NY: CRC Press; 2014.

10. National Task Force on the Prevention and Treatment of Obesity. Overweight, obesity, and health risk. Arch Intern Med. 2000;160(7):898-904.

11. National Heart, Lung, and Blood Institute. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Available at https://www.ncbi.nlm.nih.gov/books/NBK2003. Last accessed December 20, 2017.

12. Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med. 2006;355(8):763-778.

13. U.S. Department of Defense. Directive Number 1308.1: Physical Fitness and Body Fat Program. Available at http://ndri.org/docs/DoDD%201308.1%20DoD%20Physical%20Fitness%20and%20Body%20Fat%20Program.pdf. Last accessed December 20, 2017.

14. Centers for Disease Control and Prevention. Childhood Obesity Facts. Available at https://www.cdc.gov/healthyschools/obesity/facts.htm. Last accessed December 23, 2017.

15. Gallagher C. Summary of State Benchmark Plan Coverage of Obesity Treatment Services. Available at http://www.obesityaction.org/wp-content/uploads/1212-OCC-Summary-of-Obesity-Treatment-State-Benchmark-Plan-Coverage.pdf. Last accessed January 1, 2018.

16. Centers for Disease Control and Prevention. Adult Obesity Facts. Available at https://www.cdc.gov/obesity/data/adult.html. Last accessed December 23, 2017.

17. Shelton DL. Most Patients Don't See Excess Weight as Health Danger. Available at http://www.ama-assn.org/amednews/1999/pick_99/hlta1108.htm. Last accessed January 1, 2018.

18. Brown P, Bentley-Condit V. Culture, evolution and obesity. In: Bray GA, Bouchard C. Handbook of Obesity. 4th ed. New York, NY: CRC Press; 2014.

19. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372(6505):425-432.

20. Coleman DL. Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia. 1978;14(3):141-148.

21. Perusse L, Chagnon YC, Weisnagel J, Bouchard C. The human obesity gene map: the 1998 update. Obesity Research. 1999;7(1): 111-129.

22. Barlow SE, Dietz WH. Obesity evaluation and treatment: expert committee recommendations. Pediatrics. 1998;102:1-11.

23. Koplan JP, Dietz WH. Caloric imbalance and public health policy. JAMA. 1999;282(16):1579-1581.

24. National Cancer Institute. Cancer Prevention Overview. Available at https://www.cancer.gov/about-cancer/causes-prevention/hp-prevention-overview-pdq. Last accessed December 23, 2017.

25. Huang Z, Hankinson SE, Colditz GA, et al. Dual effects of weight and weight gain on breast cancer risk. JAMA. 1997;278(17):1407-1411.

26. Hinderliter A, Sherwood A, Gullette EC, et al. Reduction of left ventricular hypertrophy after exercise and weight loss in overweight patients with mild hypertension. Arch Intern Med. 2002;162:1333-1339.

27. U.S. Department of Health, Education, and Welfare. Report of the United States National Commission on Diabetes to the Congress of the United States. Pub. 76-1021. Washington, D.C.: U.S. Department of Health, Education, and Welfare; 1975.

28. Michaud DS, Giovannucci E, Willett W, et al. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA. 2001;286(8):921-929.

29. Garfinkel L. Overweight and cancer. Ann Intern Med. 1985;103:1034-1036.

30. Olson C, Schumaker H, Yawn B. Overweight women delay medical care. Arch of Fam Med. 1994;3(10):888-892.

31. Foster G., Wadden T, Phelan S, Sarwer D, Sanderson RS. Obese patients' perceptions of treatment outcomes and the factors that influence them. Arch Intern Med. 2001;161:2133-2139.

32. Blackwell DL, Lucas JW, Clarke TC. Summary health statistics for U.S. adults: National Health Interview Survey, 2012. Vital Health Stat. 2014;10(260).

33. Foster GD, Wyatt HR, Hill DO, et al. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med. 2003;348(21):2082-2090.

34. Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone Diets for weight loss and heart disease risk reduction: a randomized trial. JAMA. 2005;293:43-53.

35. Gardner CD, Kiazand A, Alhassan S, et al. Comparison of the Atkins, Zone, Ornish, and LEARN Diets for change in weight and related risk factors among overweight premenopausal women. The A TO Z Weight Loss Study: a randomized trial. JAMA. 2007;297:969-977.

36. Institutes of Medicine Food and Nutrition Board. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, DC: National Academies Press; 2005. Available at https://www.nap.edu/read/10490/chapter/1. Last accessed December 27, 2017.

37. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.

38. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.

39. Laaksonen DE, Lindström J, Lakka TA, et al. Physical activity in the prevention of type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes. 2005;54:158-165.

40. Sigal RJ, Kenny GP, Wasserman DH, Castaneda-Sceppa C, White RD. Physical activity/exercise and type 2 diabetes: a consensus statement from the American Diabetes Association. Diabetes Care. 2006;29:1433-1438.

41. Glasgow RE, Eakin EG, Fisher EB, Bacak SJ, Brownson RC. Physician advice and support for physical activity: results from a national survey. Am J Prev Med. 2001;21:189-196.

42. Centers for Disease Control and Prevention. Summary Health Statistics: National Health Interview Survey, 2015, Table A15. Available at https://ftp.cdc.gov/pub/Health_Statistics/NCHS/NHIS/SHS/2015_SHS_Table_A-15.pdf. Last accessed December 23, 2017.

43. Haskell WL, Lee IM, Pate RR, et al. Physical activity and public health: updated recommendations for adults from the American College of Sports Medicine and the American Heart Association. Circulation. 2007;116(9):1081-1093.

44. Nelson ME, Rejeski WJ, Blair SN, et al. Physical activity and public health in older adults: recommendation from the American College of Sports Medicine and the American Heart Association. Circulation. 2007;116(9):1094-1105.

45. Manson JE, Greenland P, LaCroix AZ, et al. Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med. 2002;347:716-725.

46. Castaneda C, Gordon PL, Uhlin KL, et al. Resistance training to counteract the catabolism of a low-protein diet in patients with chronic renal insufficiency. Ann Intern Med. 2001;135:965-976.

47. Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998;352:167-172.

48. Finer N, James WPT, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes. 2000;24:306-313.

49. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000;9:160-167.

50. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine—the Farmingham Study. Am J Med. 1999;106:179-184.

51. McMahon FG, Fujioka K, Singh BN, et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med. 2000;160:2185-2191.

52. Consumer Affairs. FDA Refuses to Ban Weight-Loss Drug Meridia. Available at https://www.consumeraffairs.com/fda-drug-bans. Last accessed December 31, 2017.

53. James WPT, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in over-weight and obese subjects.N Engl J Med. 2010;363:905-917.

54. Naghshizadian R, Rahnemai-Azar A, Kella K, et al. Patient perception of ideal body weight and the effect of body mass index. Journal of Obesity. 2014;(2014):491280.

55. Elder KA, Wolfe BM. Bariatric surgery: a review of procedures and outcomes. Gastroenterology. 2007;132(6):2253-2271.

56. American Society for Metabolic and Bariatric Surgery. Who is a Candidate for Bariatric Surgery? Available at https://asmbs.org/patients/who-is-a-candidate-for-bariatric-surgery. Last accessed January 1, 2018.

57. Society of American Gastrointestinal and Endoscopic Surgeons. Guidelines for the Clinical Application of Laparoscopic Bariatric Surgery. Available at https://www.sages.org/publications/guidelines/guidelines-for-clinical-application-of-laparoscopic-bariatric-surgery. Last accessed January 1, 2018.

58. Sjöström L, Lindroos A, Markku P, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683-2693.

59. Colquitt J, Clegg A, Loveman E, Royle P, Sidhu MK. Surgery for morbid obesity. Cochrane Database Syst Rev. 2005;2:CD003641.

60. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724-1737.

61. Christou NV, Sampalis JS, Liberman M, et al. Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients. Ann Surg. 2004;240(3):416-423.

62. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357(8):753-761.

63. Demaria EJ. Bariatric surgery for morbid obesity. N Engl J Med. 2007;356:2176-2183.

64. Fernandes M, Atallah AN, Soares BGO, et al. Intragastric balloon for obesity. Cochrane Database Syst Rev. 2007;1:CD004931.

65. U.S. Department of Health and Human Services. News Release: HHS Announces Revised Medicare Obesity Coverage. Available at http://nepc.colorado.edu/publication/hhs-announces-revised-medicare-obesity-coverage-policy-policy-opens-door-coverage-based-. Last accessed December 30, 2017.

66. Lee JS, Sheer JL, Lopez N, Rosenbaum S. Coverage of obesity treatment: a state-by-state analysis of Medicaid and state insurance laws. Public Health Rep. 2010;125(4):596-604.

67. Internal Revenue Service. Internal Revenue Bulletin. No. 2002-16. Available at https://www.irs.gov/pub/irs-irbs/irb02-16.pdf. Last accessed January 1, 2018.

68. Must A, Spadano J, Coakley EH, et al. The disease burden associated with overweight and obesity. JAMA. 1999;282(16):1523-1529.

69. National Heart, Lung, Blood Institute and North American Association for the Study of Obesity. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. NIH Pub. 00-4084. 2000. Available at https://www.nhlbi.nih.gov/files/docs/guidelines/prctgd_c.pdf. Last accessed December 27, 2017.

70. U.S. Department of Health and Human Services and Department of Agriculture. Dietary Guidelines for Americans, 2015–2020. Washington, DC: U.S. Department of Health and Human Services; 2015.

71. Lexicomp Online. Available at http://online.lexi.com. Last accessed December 30, 2017.

72. U.S. Food and Drug Administration. Meridia (Sibutramine Hydrochloride) Information. Available at https://wayback.archive-it.org/7993/20170406172234/https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm191652.htm. Last accessed December 31, 2017.

73. Galuska DA, Will JC, Serdula MK, Ford ES. Are health care professionals advising obese patients to lose weight? JAMA. 1999;282(16):1576-1578.

74. Centers for Disease Control and Prevention. Summary Health Statistics for U.S. Adults: National Health Interview Survey, 2012. Available at https://www.cdc.gov/nchs/data/series/sr_10/sr10_260.pdf. Last accessed December 23, 2017.

75. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief. 2020;360:1-7.

76. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291(10): 238-1245.

77. Speliotes EK, Willer CJ, Berndt SI, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet. 2010;42(11):937-948.

78. Bloss CS, Schork NJ, Topol EJ. Effect of direct-to-consumer genomewide profiling to assess disease risk. N Engl J Med. 2011;364(6):524-534.

79. Levi Z, Kark JD, Afek A, et al. Measured body mass index in adolescence and the incidence of pancreatic cancer in a cohort of 720,000 Jewish men. Cancer Causes Control. 2012;23(2):371-378.

80. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Adult weight change and risk of post-menopausal breast cancer. JAMA. 2006;296(2):193-201.

81. Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K. Central obesity and increased risk of dementia more than three decades later. Neurology. 2008;71(14):1057-1064.

82. Thomas DE, Elliott EJ, Naughton GA. Exercise for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2006;3:CD002968.

83. Centers for Disease Control and Prevention. Physical Activity for Everyone. Available at https://www.cdc.gov/physicalactivity/basics/adults/index.htm. Last accessed December 27, 2017.

84. Halpern B, Faria AM, Halpern A. Bupropion/naltrexone fixed-dose combination for the treatment of obesity. Drugs Today (Barc). 2011;47(8):575-581.

85. Nguyen NT, Masoomi H, Magno CP, Nguyen XM, Laugenour K, Lane J. Trends in use of bariatric surgery, 2003–2008. J Am Coll Surg. 2011;213(2):261-266.

86. Dumon KR, Murayama KM. Bariatric surgery outcomes. Surg Clin North Am. 2011;91(6):1313-1338.

87. Mechanick JI, Kushner RF, Sugerman HJ, et al. American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic and Bariatric Surgery Medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. Endocr Pract. 2008;14(Suppl 1):1-83.

88. Nath A, Leblanc KA, Hausmann MG, Kleinpeter K, Allain BW, Romero R. Laparoscopic sleeve gastrectomy: our first 100 patients. JSLS. 2010;14(4):502-508.

89. Fuks D, Verhaeghe P, Brehant O, et al. Results of laparoscopic sleeve gastrectomy: a prospective study in 135 patients with morbid obesity. Surgery. 2009;145(1):106-113.

90. Jan JC, Hong D, Pereira N, Patterson EJ. Laparoscopic adjustable gastric banding versus laparoscopic gastric bypass for morbid obesity: a single-institution comparison study of early results. J Gastrointest Surg. 2005;9(1):30-39.

91. Tice JA, Karliner L, Walsh J, Petersen AJ, Feldman MD. Gastric banding or bypass? A systematic review comparing the two most popular bariatric procedures. Am J Med. 2008;121(10):885-893.

92. Boza C, Gamboa C, Perez G, et al. Laparoscopic adjustable gastric banding (LAGB): surgical results and 5-year follow-up. Surg Endosc. 2011;25(1):292-297.

93. Centers for Medicare and Medicaid Services. National Coverage Determination (NCD) for Bariatric Surgery for Treatment of Morbid Obesity (100.1). Available at https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=57&ncdver=5&bc=AAAAQAAAAAAAAA%3d%3d&. Last accessed January 1, 2018.

94. Centers for Medicare and Medicaid Services. National Coverage Determination (NCD) for Intensive Behavioral Therapy for OBESITY (210.12). Available at https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=353&ncdver=1&CoverageSelection=Both&ArticleType=All&PolicyType=Final&s=All&KeyWord=obesity&KeyWordLookUp=Title&KeyWordSearchType=And&bc=gAAAABAAAAAA&. Last accessed January 1, 2018.

95. U.S. Food and Drug Administration. FDA Briefing Document: NDA 22529 Lorcaserin Hydrochloride Tablets. Available at https://wayback.archive-it.org/7993/20170405220658/https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM225631.pdf. Last accessed December 30, 2017.

96. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245-256.

97. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96(10):3067-3077.

98. U.S. Food and Drug Administration. Press Release: FDA Approves Weight-Management Drug Qsymia. Available at https://www.aace.com/article/185. Last accessed December 30, 2017.

99. U.S. Food and Drug Administration. FDA Approves Weight-Management Drug Contrave. Available at https://wayback.archive-it.org/7993/20170112222826/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm413896.htm. Last accessed December 30, 2017.

100. Abid A, Galuska D, Khan LK, Gillespie C, Ford ES, Serdula MK. Are healthcare professionals advising obese patients to lose weight? A trend analysis. MedGenMed. 2005;7(4):10.

101. Bishop J, Middendorf R, Babin T, Tilson W. ASPE Research Brief: Childhood Obesity. Available at https://aspe.hhs.gov/basic-report/aspe-childhood-obesity-white-paper. Last accessed December 23, 2017.

102. Tsai AG, Williamson DF, Glick HA. Direct medical cost of overweight and obesity in the USA: a quantitative systematic review. Obes Rev. 2011;12(1):50-61.

103. O'Brien PE, MacDonald L, Anderson M, Brennan L, Brown WA. Long-term outcomes after bariatric surgery: fifteen-year follow-up of adjustable gastric banding and a systematic review of the bariatric surgical literature. Ann Surg. 2013;257(1):87-94.

104. American Society for Metabolic and Bariatric Surgery. Estimate of Bariatric Surgery Numbers. Available at https://asmbs.org/resources/estimate-of-bariatric-surgery-numbers. Last accessed January 1, 2018.

105. American Society for Metabolic and Bariatric Surgery. Studies Weigh in on Safety and Effectiveness of Newer Bariatric and Metabolic Surgery Procedure. Available at https://asmbs.org/resources/studies-weigh-in-on-safety-and-effectiveness-of-newer-bariatric-and-metabolic-surgery-procedure. Last accessed January 1, 2018.

106. Centers for Medicare and Medicaid Services. Bariatric Surgery. Available at https://www.cms.gov/Medicare/Medicare-General-Information/MedicareApprovedFacilitie/Bariatric-Surgery.html. Last accessed January 1, 2018.

107. Downey M, Still CD. The Affordable Care Act's Impact on Persons with Obesity. Available at http://www.downeyobesityreport.com/wp-content/uploads//The-Affordable-Care-Act2.pdf. Last accessed January 1, 2018.

108. U.S. Department of Labor. The Affordable Care Act and Wellness Programs. Available at https://www.dol.gov/agencies/ebsa/laws-and-regulations/laws/affordable-care-act. Last accessed January 1, 2018.

109. U.S. Food and Drug Administration. FDA Approves Weight-Management Drug Saxenda. Available at https://wayback.archive-it.org/7993/20170111160832/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427913.htm. Last accessed December 30, 2017.

110. Ogden CL. Carroll MD, Lawman HG, et al. Trends in obesity prevalence among children and adolescents in the United States, 1988–1994 through 2013–2014. JAMA. 2016;315(21):2292-2299.

111. Locke AE, Kahali B, Berndt SI, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518(7538):197-206.

112. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC guideline for the management of overweight and obesity in adults. Circulation. 2014;129(25 Suppl 2):S102-S138.

113. Johnston BC, Kanters S, Bandayrel K, et al. Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis. JAMA. 2014;312(9):923-933.

114. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014;311(1):74-86.

115. Puzziferri N, Roshek TB, Mayo HG, et al. Long-term follow-up after bariatric surgery: a systematic review. JAMA. 2014;312(9):934-942.

116. U.S. Food and Drug Administration. Update: Potential Risks with Liquid-Filled Intragastric Balloons—Letter to Health Care Providers. Available at https://www.fda.gov/MedicalDevices/Safety/LetterstoHealthCareProviders/ucm570707.htm. Last accessed January 1, 2018.

117. U.S. Food and Drug Administration. The FDA Alerts Health Care Providers about Potential Risks with Liquid-Filled Intragastric Balloons. Available at https://www.fda.gov/medicaldevices/resourcesforyou/healthcareproviders/ucm540655.htm. Last accessed January 1, 2018.

118. U.S. Food and Drug Administration. ORBERA Intragastric Balloon System: P140008. Available at https://www.accessdata.fda.gov/cdrh_docs/pdf14/P140008c.pdf. Last accessed January 1, 2018.

119. U.S. Food and Drug Administration. FDA Approves First-of-Kind Device to Treat Obesity. Available at https://www.sciencedaily.com/releases/2015/01/150129170327.htm. Last accessed January 1, 2018.

Evidence-Based Practice Recommendations Citations

1. U.S. Preventive Services Task Force. Behavioral weight loss interventions to prevent obesity-related morbidity and mortality in adults: U.S. Preventive Services Task Force recommendation statement. JAMA. 2018;320(11):1163-1171. Available at https://jamanetwork.com/journals/jama/fullarticle/2702878. Last accessed March 2, 2020.

2. Department of Veterans Affairs Management of Overweight and Obesity Working Group. VA/DoD Clinical Practice Guideline for Screening and Management of Overweight and Obesity. Washington, DC: Department of Veterans Affairs, Department of Defense; 2014. Available at https://www.healthquality.va.gov/guidelines/CD/obesity. Last accessed March 2, 2020.

3. University of Michigan Health System. Obesity Prevention and Management. Ann Arbor, MI: University of Michigan Health System; 2019. Available at https://www.med.umich.edu/1info/FHP/practiceguides/obesity/obesity.pdf. Last accessed March 2, 2020.


Copyright © 2018 NetCE, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.